Lauriane Eberst

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study).

Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study).

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 23, 2026

Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53).

Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53).

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 27, 2025

French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced/relapsing endometrial cancer

French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced/relapsing endometrial cancer

Journal: Bulletin du cancer

Published: October 24, 2025

Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort.

Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort.

Journal: Journal of clinical medicine

Published: August 11, 2025

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Journal: Future oncology (London, England)

Published: August 19, 2024

Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.

Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: March 01, 2024

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

Journal: The Lancet. Oncology

Published: February 23, 2024

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.

Journal: Science translational medicine

Published: January 24, 2024

PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.

PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.

Journal: The oncologist

Published: January 23, 2024

Variability of treatment of locally advanced cervical cancer: How French multidisciplinary teams follow European guidelines?

Variability of treatment of locally advanced cervical cancer: How French multidisciplinary teams follow European guidelines?

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 07, 2024

Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.

Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 09, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026